Pharmbio Korea Inc.

Israeli firm Kamada has struck a deal with Alvotech that gives it rights to market six Alvotech biosimilars in Israel. The first of these will be teriparatide, which is slated for a 2022 launch, w

Pfenex believes it and commercial partner Alvogen could benefit from an extended period as the only direct competition to Eli Lilly’s Forteo (teriparatide) osteoporosis blockbuster in the US. Howev

Alvogen has entered into exclusive commercial agreements in Canada, Israel and South Korea for the PF708 teriparatide candidate developed by its partner Pfenex . The Icelandic company has struck dea